S Nolden
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
S Nolden has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
A Kuhn
Dermatohistologisches Gemeinschaftsabor, 50997 Cologne, Germany
1 shared publicationC Casper
Dermatohistologisches Gemeinschaftsabor, 50997 Cologne, Germany
1 shared publicationH F Petereit
Department of Neurology, University of Cologne, 50924 Cologne, Germany
1 shared publication
Latest Publications
- 1 April 2005
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 11 (2) , 245-248
Jessner-Kanof lymphocytic infiltration of the skin associated with glatiramer acetate
Glatiramer acetate (GLAT) is a well tolerated and safe immunomodulatory drug for the treatment of relapsing=remitting multiple sclerosis. The most commonly recognized side effects are localized injection site reactions consisting of pain, pruritus, mild erythema and induration, which sometimes persist for several days. We describe the first case of a biopsy-proven lymphocytic infiltration (T-cell pseudolymphoma) with the clinical appearance of a figured erythema on the ventrolateral thighs in the first four weeks under GLAT treatment, resolving without any evidence of recurrence despite ongoing therapy. A T-cell pseudolymphoma is a very rare side effect of GLAT treatment. For clinical purposes it is important to state that re-exposition after GLAT-induced pseudolymphoma is possible without permanent sequelae.
- 1 April 2005
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 11 (2) , 245-248
Jessner-Kanof lymphocytic infiltration of the skin associated with glatiramer acetate
Glatiramer acetate (GLAT) is a well tolerated and safe immunomodulatory drug for the treatment of relapsing=remitting multiple sclerosis. The most commonly recognized side effects are localized injection site reactions consisting of pain, pruritus, mild erythema and induration, which sometimes persist for several days. We describe the first case of a biopsy-proven lymphocytic infiltration (T-cell pseudolymphoma) with the clinical appearance of a figured erythema on the ventrolateral thighs in the first four weeks under GLAT treatment, resolving without any evidence of recurrence despite ongoing therapy. A T-cell pseudolymphoma is a very rare side effect of GLAT treatment. For clinical purposes it is important to state that re-exposition after GLAT-induced pseudolymphoma is possible without permanent sequelae.